
    
      This is a multi-center, randomized, double-masked, placebo (vehicle)-controlled study,
      designed to evaluate the efficacy and safety of OCS-01 ophthalmic suspension (QD versus BID)
      compared to placebo in treating inflammation and pain following cataract surgery. Subjects
      will be randomized 1:1:1 to receive OCS-01 QD, OCS-01 BID, or placebo BID. Subjects will dose
      1 drop in the study eye BID for 14 days, beginning 1 day post-surgery in the operated eye.
      The study will last up to 24 days, including a follow-up visit at Visit 7 (Day 22 Â± 2).
    
  